In support of the above, preclinical studies have demonstrated that inhibition of IDO1 can be effective in combination with B cell depletion therapy in the treatment of RA [61], as well as in managing SLE-associated fatigue [246], morphea [77], and other cutaneous sclerosing disorders [247]. Here, IDO1 is linked to systemic lupus erythematosus.